Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Microbiome Cancer Immunotherapy Project Aims To Improve Oncology Drugs

XTALKS VITALS NEWS

Microbiome

While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Tweetables from this article:

Tweet: New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs http://ctt.ec/5a6gw+New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs.

Tweet: Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases http://ctt.ec/5md0J+Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases.

Share this!

August 15, 2016 | by Sarah Massey, M.Sc.

A new class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs, are set to be developed by Vedanta Biosciences and NYU Langone Medical Center. While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Earlier this year, Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases. The company – founded by PureTech Health – hopes to get these drugs into the clinic in 2017.

“Dr. Weber is a pioneer in translational research, particularly in immunotherapy and the development of checkpoint inhibitors,” said CSO of Vedanta, Bruce Roberts, commenting on the leader of the project. “We look forward to working with Dr. Weber to expand Vedanta’s portfolio of immune activating microbial cocktails for use in standalone immunotherapy and in combination with checkpoint inhibitors.”



Verdanta’s interest in oncology comes at a turbulent time in microbiome therapeutics research. A Phase II clinical trial of an oral microbiome drug, led by Seres Therapeutics, failed to meet its endpoint of reducing the risk of Clostridium difficile infection.

The company’s collaboration with NYU aims to investigate the mechanisms by which gut bacteria impact checkpoint inhibitor drug efficacy as a cancer therapy. Vedanta researchers believe that human gut bacteria could be harnessed to develop effective immunotherapies.

“Checkpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy, and some patients who respond will eventually relapse,” said Dr. Jeffrey Weber, who is the deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone. “Recent data suggest an important role for the microbiome in the anti-tumor activity of immunotherapy, and our other studies of the microbiome will offer interesting new clinical insights into how and why these treatments work.”


Keywords: Microbiome, Immunotherapy, Oncology


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.